On May 25, 2021 Oxford Cannabinoid Technologies Holdings Plc, the holding company of Oxford Cannabinoid Technologies Ltd (OCT), reported that debuted on the Main Market of the LSEG (London Stock Exchange Group) on 21st May, 2021 (Press release, AskAt, MAY 25, 2021, View Source [SID1234580528]). OCT is a UK-based pharmaceutical company currently developing AAT-730 (OCT461201), a CB2 receptor agonist licensed from AskAt Inc.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to OCT’s prospectus, the company will allocate approximately ₤3.5 million from the offering proceeds to the development of AAT-730. Actually, AAT-730 is one of the OCT’s most advanced program and their first priority will be completing the preclinical development and CMC production of AAT-730, followed by entry into Phase 1 clinical trials in the Third Quarter of 2022.